国内药企扎堆在美国开展临床试验,创新药全球化发展迈入新阶段

制药网
Jan 23

近年来,在监管优化、全球商业化刚需、临床资源优势与资本 / BD 驱动下,国内药企正密集在美国开展临床试验 。据悉,2026年截至1 月 23 日,百济神州、荣昌生物、恒瑞医药、信达生物、康方生物等至少40家药企就已公告在美获批临床及完成头例患者给药等消息。如近日,迈威生物宣布其靶向 CDH17 ADC 创新药(研发代号:7MW4911)用于晚期结直肠癌及其他晚期胃肠道肿瘤患者的临床试验在美国完成...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10